Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
AVXL

Anavex Life Sciences Corp.

AVXL

NASDAQ·Healthcare·Biotechnology·Mkt cap $265.0M

$2.86

▲ +0.35%

P/E

-20.43

Mkt Cap

$265.0M

52-Wk Range

$2.26–$10.40

52-Week Range

$2.26 - $10.40

P/E

-20.43

Fwd P/E

-8.67

Beta

1.14

Div Yield

0.00%

Avg Vol

1.1M

Shares Out

92.7M

Mkt Cap

$265.0M

Price action

Price chart

Down 69.4% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Proprietary sigma receptor agonist platform with broad CNS applications
  • Advanced clinical pipeline with Phase III trials in large-market indications
  • Multi-indication potential for lead candidate ANAVEX 2-73 reducing development risk
  • Orphan drug designations providing regulatory advantages and market exclusivity
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Phase III clinical trial results for ANAVEX 2-73 in Alzheimer's disease and Rett syndrome

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Strong

+9.2% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 24, 2026

“
Q3 26 RECAP

AUG 21, 2026

Reported EPS of -$0.06 vs -$0.08 consensus (+25.0% surprise).

EPS beat +25.0%

EPS surprise · last 4Q

3 of 3 beats

Estimate

Actual

Q3 26

+25.0%

Q3 26

+25.0%

Q3 26

+14.3%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q4 24

Q1 24

Q2 25

Q3 25

Q4 25

Q1 25

Q2 26

Q3 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

1 analyst · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

1

100%

Hold

0%

Sell

0%

Median Price Target

—

Latest: D. Boral Capital · Mar 31, 2026

View full analyst page →

vs Industry

How AVXL stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.